Delving into the Latest Updates on Beijing Golden Lion Biopharmaceutical Technology Development Co., Ltd. with Synapse

Overview

To further study the efficacy of topical recombinant human platelet-derived growth factor (100ug/g) in the treatment of chronic diabetic lower limb skin ulcers and estimate its effectiveness in ulcer healing; to further observe the safety of topical rhPDGF-BB gel (100ug/g) in the treatment of chronic diabetic lower limb skin ulcers.

Start Date27 Jun 2013

Sponsor / Collaborator

Beijing Golden Lion Biopharmaceutical Technology Development Co., Ltd.

[+1]

100 Clinical Results associated with Beijing Golden Lion Biopharmaceutical Technology Development Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Golden Lion Biopharmaceutical Technology Development Co., Ltd.

Login to view more data

100 Deals associated with Beijing Golden Lion Biopharmaceutical Technology Development Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Golden Lion Biopharmaceutical Technology Development Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human platelet-derived growth factor(Beijing Jinsaishi Biopharmaceutical Technology Development Co Ltd) ( PDGFRs )	Diabetic Foot More	Discontinued
Recombinant human interferon β1b(Beijing Jinsaishi Biopharmaceutical Technology Development Co Ltd) ( IFNAR )	Multiple Sclerosis More	Discontinued